Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to examine the effect of intensive cholesterol lowering therapy and tight blood pressure (BP) regulation on endothelial function (inner cell layer of vessels that determines dilatation) in type 2 diabetic patients without documented cardiovascular (CV) disease. The hypothesis is that intensive cholesterol lowering and tight blood pressure regulation will due better than a control group.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Southern Denmark
• Collaborator: Pfizer
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus,

• Total cholesterol <6.5 mmol/l

• Signed informed consent

Exclusion Criteria:

• Documented CAD or peripheral vascular disease

• Treatment with lipid-lowering drugs

• Contraindications to HMG-CoA reductase therapy

• Potential noncompliance